OrchidPharma
A Dhanuka Group Company

November 16, 2026

National Stock Exchange of India Limited,
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai-400051

Symbol: **ORCHPHARMA**

BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort, Mumbai-400001

Scrip Code: **524372**

Ref: (i) Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015
(ii) SEBI Circular No. SEBI/HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026

Sub: Investors Presentation- Quarter II of F.Y. 2026-27, ended on September 30, 2026 – Orchid Pharma Limited ("the Company")

Dear Sir/Madam,

With reference to the captioned subject and pursuant to Regulation 30, Sub- Para 15 of Para A of Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended read with SEBI Circular no. SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31, 2024 and in continuation to our earlier intimation, dated November 12, 2026, regarding the Analysts/Investors Earning Call scheduled to be held on November 17, 2026 at 04:30 P.M. (IST), please find enclosed the Investors Presentation, inter-alia, including the financial performance of the Company for the Quarter-II of Financial Year 2026-27, ended on September 30, 2026.

The Investor Presentation is also made available on the website of the Company at https://www.orchidpharma.com/investors

You are requested to take the above intimation on record.

Thanking You,
For **Orchid Pharma Limited**
KAPIL DAYYA
Digitally signed by KAPIL DAYYA
Date: 2026.11.16 18:41:40 +05'30'
Kapil Dayya
Company Secretary & Compliance Officer
Mem. No.- F10698

Encl. as above

FROM

Soil to Vial

OrchidPharma
A Dhanuka Group Company



Nature Inspired Origins

Fermentation & Biotransformation

KSMs & API Process Development

API Manufacturing

Formulations & Fill Finish

Finished Dosage For A Healthier World

2026

Safe Harbor

This presentation and the accompanying slides (the "Presentation"), which have been prepared by **Orchid Pharma Limited (**the "Company'), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

Certain matters discussed in this Presentation may contain statements regarding the Company's market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the company's ability to successfully implement its strategy, the Company's future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cashflows, the Company's market preferences and its exposure to market risks, as well as other risks. The Company's levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third-party statements and projections.

All Maps used in the presentation are not to scale. All data, information, and maps are provided "as is" without warranty or any representation of accuracy, timeliness or completeness.

Orchid Pharma Limited

One of the most **integrated** anti-infective platform globally

- Built on **30 years of cephalosporin expertise.**
- Proven by **EXBLIFEP - India's only novel antibiotic.**
- Anchored by **India's only USFDA sterile cephalosporin approval.**
- Extending into **AMR and regulated markets.**

OrchidPharma
A Dhanuka Group Company

A significantly large anti-infectives business built on an integrated foundation


Scale + Integration

A strong participant in selected high-value and regulated opportunities

Regulated Markets

Positioned for sustained long-term growth

Structural Growth



A differentiated cephalosporin platform spanning KSM to finished dosage

Full Value Chain

A business combining scale, integration, innovation and disciplined expansion

Four Pillars



An Integrated Cephalosporin Platform

- Orchid is at an inflection point
- The merger is complete and the platform is coming together as one
- The core API business is ready to create long-term value
- Multiple growth engines are moving from concept to execution across KSM, FDF, and Innovative drug products


STRATEGIC AMALGAMATION

Two entities. One Orchid.

Dhanuka Laboratories Ltd. amalgamated into Orchid Pharma Ltd. under the NCLT-sanctioned Scheme.

APPOINTED DATE
1 April 2024

EFFECTIVE DATE
10 July 2026



EXBLIFEP · BUSINESS DEVELOPMENT

Signed licensing partnerships

Pharmasyntez

RUSSIA · 1 MARKET

US$ 178 M

Estimated sales potential

Markets Covered: Russian Federation

Laboratorio Libra

LATIN AMERICA · 9 MARKETS

US$ 80 M

Estimated sales potential

Markets Covered: Chile · Uruguay · Panama · El Salvador · Guatemala · Ecuador · Honduras · Paraguay · Costa Rica

COMBINED **US$ 258 M** across 10 markets · 2 signed partners

Financial Performance

Q2 FY27



Q2 FY27 Financial Performance : **Standalone**


(Rs Cr)

(Amt. in Cr.)	Q2-27	Q2-26	% Change	H1-27	H1-26	% Change
Revenue from Operations	341	298	+14%	645	562	+15%
Other Income	29	16	+76%	39	32	+20%
COGS	208	207		413	390	
Employee Exp	33	31		59	58	
Other Exp	77	57		135	115	
EBITDA	52	20	+148%	77	31	+151%
% to Sales	15%	7%		12%	5%	
Interest	4	3		6	5	+21%
Depreciation	11	11		22	21	
Exceptional Items	–	–		–	–	
PAT	37	7		49	5	


Q2 FY27 Financial Performance : **Standalone**

(Rs Cr)


Total Revenue




EBITDA




PAT



Gross Margin




EBITDA Margin (%)




H1 FY27 Financial Performance : **Standalone**

(Rs Cr)


Total Revenue




EBITDA




PAT



Gross Margin



EBITDA Margin (%)



Profit & Loss Statement (Standalone)

(Rs Cr)

Particulars	Q2 FY27 Sep 2026	Q1 FY27 Jun 2026	Q2 FY26 Sep 2025	H1 FY27 Sep 2026	H1 FY26 Sep 2025	FY26 Year ended
Income						
Revenue from Operations	341.27	304.17	298.46	645.44	561.64	1,232.78
Other Income	28.63	10.05	16.29	38.68	32.34	56.49
Total Income	**369.90**	**314.22**	**314.75**	**684.12**	**593.99**	**1,289.27**
Expenses						
Cost of Materials Consumed	245.96	206.42	172.05	452.38	375.75	771.39
Changes in Inventories	(38.95)	(2.72)	34.79	(41.67)	13.69	71.38
Purchases of Stock-in-Trade	1.42	0.61	0.17	2.03	0.96	1.69
Employee Benefits Expense	32.69	26.76	30.64	59.44	58.34	114.32
Finance Costs	3.66	2.21	2.57	5.87	4.85	8.96
Depreciation & Amortisation	11.32	10.90	10.70	22.22	21.24	43.36
Other Expenses	77.04	58.11	56.92	135.15	114.66	236.21
Total Expenses	**333.14**	**302.28**	**307.84**	**635.42**	**589.48**	**1,247.31**
Profit/(Loss) Before Exceptional Items & Tax	**36.76**	**11.94**	**6.91**	**48.70**	**4.50**	**41.95**
Exceptional Items	–	–	–	–	–	(7.33)
Profit/(Loss) Before Tax	**36.76**	**11.94**	**6.91**	**48.70**	**4.50**	**34.62**
Tax Expense	–	–	–	–	–	–
Share of Profit/(Loss) of Associates & JV	–	–	–	–	–	–
Profit/(Loss) for the Period	**36.76**	**11.94**	**6.91**	**48.70**	**4.50**	**34.62**
Other Comprehensive Income (net of tax)	(0.31)	0.01	(0.39)	(0.30)	(0.55)	1.32
Total Comprehensive Income	**36.45**	**11.94**	**6.51**	**48.40**	**3.96**	**35.94**
EPS — Basic & Diluted (₹)	**6.14**	**1.99**	**1.15**	**8.13**	**0.75**	**5.78**

Profit & Loss Statement (Consolidated)

(Rs Cr)

Particulars	Q2 FY27 Sep 2026	Q1 FY27 Jun 2026	Q2 FY26 Sep 2025	H1 FY27 Sep 2026	H1 FY26 Sep 2025	FY26 Year ended
Income						
Revenue from Operations	341.27	304.17	298.46	645.44	561.64	1,232.78
Other Income	17.76	1.83	11.64	19.58	23.21	36.42
Total Income	**359.02**	**306.00**	**310.10**	**665.02**	**584.85**	**1,269.20**
Expenses						
Cost of Materials Consumed	245.96	206.42	172.05	452.38	375.75	771.39
Changes in Inventories	(38.95)	(2.72)	34.79	(41.67)	13.69	71.38
Purchases of Stock-in-Trade	1.42	0.61	0.17	2.03	0.96	1.69
Employee Benefits Expense	31.41	28.04	31.44	59.44	59.14	117.65
Finance Costs	3.64	2.23	2.57	5.87	4.85	8.98
Depreciation & Amortisation	11.41	10.95	10.81	22.36	21.35	43.25
Other Expenses	77.29	57.83	56.92	135.12	114.66	237.09
Total Expenses	**332.19**	**303.35**	**308.76**	**635.54**	**590.40**	**1,251.44**
Profit/(Loss) Before Exceptional Items & Tax	**26.84**	**2.65**	**1.34**	**29.49**	**(5.55)**	**17.76**
Exceptional Items	–	–	–	–	–	(7.33)
Profit/(Loss) Before Tax	**26.84**	**2.65**	**1.34**	**29.49**	**(5.55)**	**10.43**
Tax Expense	(0.04)	0.07	(0.15)	0.03	(0.15)	(0.19)
Share of Profit/(Loss) of Associates & JV	1.71	0.65	(2.39)	2.36	(1.19)	(0.66)
Profit/(Loss) for the Period	**28.59**	**3.22**	**(0.90)**	**31.82**	**(6.59)**	**9.96**
Other Comprehensive Income (net of tax)	(0.31)	0.01	(0.39)	(0.30)	(0.55)	1.32
Total Comprehensive Income	**28.29**	**3.23**	**(1.29)**	**(31.52**	**(7.14)**	**11.28**
EPS — Basic & Diluted (₹)	**4.77**	**0.54**	**(0.15)**	**5.31**	**(1.1)**	**1.66**

Balance Sheet (Standalone)

(Rs Cr)

Assets	30 Sep 2026 Unaudited	31 Mar 2026 Audited
Non-current assets		
Property, plant & equipment	696.60	665.07
Intangible assets	62.28	0.60
Capital work-in-progress	196.12	95.00
Intangibles under development	15.85	73.08
Right-of-use assets	4.61	4.93
Investments	73.34	87.59
Loans to subsidiaries	362.65	182.49
Other financial assets	9.27	6.61
Non-current tax assets (net)	60.45	59.82
Other non-current assets	7.79	41.01
Total non-current assets	**1,488.96**	**1,216.19**
Current assets		
Inventories	422.11	372.31
Trade receivables	348.16	381.35
Cash & cash equivalents	23.93	1.30
Bank balances (other)	3.49	65.21
Other financial assets	1.86	1.06
Other current assets	78.40	60.20
Total current assets	**877.95**	**881.44**
Total Assets	**2,366.91**	**2,097.63**

Equity & Liabilities	30 Sep 2026 Unaudited	31 Mar 2026 Audited
Equity		
Equity share capital	59.89	59.89
Other equity	1,633.14	1,586.79
Total equity	**1,693.02**	**1,646.68**
Non-current liabilities		
Borrowings	101.25	35.63
Lease liabilities	4.55	4.72
Provisions	7.96	13.45
Other non-current liabilities	9.53	2.12
Total non-current liabilities	**123.29**	**55.92**
Current liabilities		
Borrowings	175.80	87.91
Lease liabilities	0.37	0.39
Trade payables — MSME	11.95	10.30
Trade payables — others	326.06	266.08
Other financial liabilities	–	1.34
Short-term provisions	2.02	0.80
Other current liabilities	34.40	28.22
Total current liabilities	**550.60**	**395.04**
Total Equity & Liabilities	**2,366.91**	**2,097.63**

Balance Sheet (Consolidated)

(Rs Cr)

Assets	30 Sep 2026 Unaudited	31 Mar 2026 Audited
Non-current assets		
Property, plant & equipment	722.20	686.61
Intangible assets	62.28	0.60
Capital work-in-progress	688.12	340.52
Intangibles under development	24.98	73.08
Right-of-use assets	4.61	4.93
Investments	54.90	66.97
Other financial assets	14.36	6.61
Non-current tax assets (net)	60.45	59.91
Other non-current assets	65.47	89.95
Total non-current assets	**1,697.36**	**1,329.16**
Current assets		
Inventories	422.11	372.31
Trade receivables	348.16	381.35
Cash & cash equivalents	46.62	7.07
Bank balances (other)	9.65	76.45
Other financial assets	1.43	1.29
Current & deferred tax assets	0.40	0.29
Other current assets	126.63	90.50
Total current assets	**954.99**	**929.26**
Total Assets	**2,652.35**	**2,258.43**

Equity & Liabilities	30 Sep 2026 Unaudited	31 Mar 2026 Audited
Equity		
Equity share capital	59.89	59.89
Other equity	1,572.40	1,504.42
Total equity	**1,632.28**	**1,564.31**
Non-current liabilities		
Borrowings	339.06	184.74
Lease liabilities	4.55	4.72
Provisions	7.96	13.45
Other non-current liabilities	16.18	–
Total non-current liabilities	**367.74**	**202.91**
Current liabilities		
Borrowings	204.60	116.70
Lease liabilities	0.37	0.39
Trade payables — MSME	11.95	10.30
Trade payables — others	384.39	336.41
Other financial liabilities	–	1.34
Short-term provisions	2.02	0.80
Other current liabilities	49.01	25.27
Total current liabilities	**652.33**	**491.21**
Total Equity & Liabilities	**2,652.35**	**2,258.43**

Balance Sheet (Consolidated) Highlights

TOTAL ASSETS

₹ 2,652 Cr

31 Mar 26: ₹ 2,258 Cr

NET WORTH

₹ 1,632 Cr

31 Mar 26: ₹ 1,564 Cr

NET DEBT

₹ 487 Cr

31 Mar 26: ₹ 218 Cr

DEBT / EQUITY

0.33x

31 Mar 26: 0.19x

(Rs Cr)

Particulars	30 Sep 2026	31 Mar 2026	Change
Non-current assets	1,697	1,329	+368
Current assets	955	929	+26
Total Assets	**2,652**	**2,258**	**+394**
Shareholders' equity	1,632	1,564	+68
Gross borrowings	544	301	+243
Other liabilities	476	393	+83
Total Equity & Liabilities	**2,652**	**2,258**	**+394**

Non-current assets up ₹368 Cr, led by capital work-in-progress on the 7ACA and Cefiderocol projects; funded partly by incremental borrowings.

Cash Flow Statement

(Rs Cr)

Particulars	Standalone		Consolidated	
	H1 FY27 30 Sep 2026	H1 FY26 30 Sep 2025	H1 FY27 30 Sep 2026	H1 FY26 30 Sep 2025
Profit/ loss Before Income Tax	**48.70**	**4.50**	**29.49**	**(6.74)**
Adjustments for: Non-Cash Items / Other Investment or Financial Items	11.67	2.77	26.44	10.94
Operating profit before Working Capital Changes	**60.37**	**7.27**	**55.92**	**4.20**
Changes in Working Capital	30.98	(10.95)	62.54	(11.98)
Cash Generated from Operations	**91.34**	**(3.68)**	**118.46**	**(7.78)**
Direct taxes paid (net of refund)	(0.63)	3.11	(0.68)	3.07
Net Cash from Operating Activities	**90.71**	**(0.57)**	**117.78**	**(4.70)**
Net Cash from Investing Activities	**(214.39)**	**8.98**	**(314.58)**	**(72.48)**
Net Cash from Financing Activities	**146.30**	**13.71**	**236.34**	**98.08**
Net Increase / (Decrease) in Cash and Cash equivalents	**22.62**	**22.12**	**39.55**	**20.89**
Add: Cash & Cash equivalents at the beginning of the period	1.30	15.94	7.07	21.18
Cash & Cash equivalents at the end of the period	**23.93**	**38.06**	**46.62**	**42.07**


OrchidPharma
A Dhanuka Group Company